Christopher Paul Rusconi
Keine laufenden Positionen mehr
Karriereverlauf von Christopher Paul Rusconi
Ehemalige bekannte Positionen von Christopher Paul Rusconi
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Duke University Medical Center | Corporate Officer/Principal | - | - |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 29.04.2009 | - |
| Gründer | 21.12.2009 | - |
Ausbildung von Christopher Paul Rusconi
| University of Kansas | Undergraduate Degree |
| University of Colorado Boulder | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
